Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications
Open Access
- 19 August 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica Communications
- Vol. 3 (1), 1-11
- https://doi.org/10.1186/s40478-015-0229-8
Abstract
The term atypical pituitary adenoma (APA) was revised in the 2004 World Health Organization (WHO) classification of pituitary tumors. However, two of the four parameters required for the diagnosis of APAs were formulated rather vaguely (i.e., “extensive” nuclear staining for p53; “elevated” mitotic index). Based on a case-control study using a representative cohort of typical pituitary adenomas and APAs selected from the German Pituitary Tumor Registry, we aimed to obtain reliable cut-off values for both p53 and the mitotic index. In addition, we analyzed the impact of all four individual parameters (invasiveness, Ki67-index, p53, mitotic index) on the selectivity for differentiating both adenoma subtypes. Of the 308 patients included in the study, 98 were diagnosed as APAs (incidence 2.9 %) and 10 patients suffered from a pituitary carcinoma (incidence 0.2 %). As a control group, we selected 200 group matched patients with typical pituitary adenomas (TPAs). Cut-off values were attained using ROC analysis. We determined significant threshold values for p53 (≥2 %; AUC: 0.94) and the mitotic index (≥2 mitosis within 10 high power fields; AUC: 0.89). The most reliable individual marker for differentiating TPAs and APAs was a Ki-67-labeling index ≥ 4 % (AUC: 0.98). Using logistic regression analysis (LRA) we were able to show that all four criteria (Ki-67 (p < 0.001); OR 5.2// p53 (p < 0.001); OR 3.1// mitotic index (p < 0.001); OR 2.1// invasiveness (p < 0.001); OR 8.2)) were significant for the group of APAs. Furthermore, we describe the presence of nucleoli as a new favorable parameter for TPAs (p = 0.008; OR: 0.4; CI95 %: 0.18; 0.77). Here we present a proposed rectification of the current WHO classification of pituitary tumors describing an additional marker for TPA and specific threshold values for p53 and the mitotic index. This will greatly help in the reliable diagnosis of APAs and facilitate further studies to ascertain the prognostic relevance of this categorization.Keywords
Funding Information
- Novartis Pharma GmbH Nuremberg (ID0ETAAE153)
- Novo Nordisk Pharma GmbH Mainz (ID0E4BAE154)
- Pfizer Pharma GmbH Karlsruhe (ID0EHDAE155)
- Ipsen Pharma GmbH (ID0EREAE156)
This publication has 80 references indexed in Scilit:
- Silent Corticotroph Adenoma with Adrenal Cortical Choristoma: a Rare but Distinct Morphological EntityEndocrine Pathology, 2013
- Pituitary Carcinoma: Difficult Diagnosis and TreatmentJournal of Clinical Endocrinology & Metabolism, 2011
- Giant Pituitary AdenomasThe American Journal of Surgical Pathology, 2011
- Therapy of aggressive pituitary tumorsExpert Opinion on Pharmacotherapy, 2011
- Atypical pituitary adenomas: incidence, clinical characteristics, and implicationsJournal of Neurosurgery, 2011
- Best Practice No 172: Pituitary gland pathologyJournal of Clinical Pathology, 2003
- Symptomatic pituitary metastasesJournal of Neurosurgery, 1998
- P53 protein accumulates in Cushings adenomas and invasive non- functional adenomas [corrected and republished article originally printed in J Clin Endocrinol Metab 1994 Nov;79(5):1513-6]Journal of Clinical Endocrinology & Metabolism, 1995
- Pituitary carcinomaClinical Endocrinology, 1992
- Basic principles of ROC analysisSeminars in Nuclear Medicine, 1978